Why do we Still Use 5-ASAs in Crohn's Disease?

Stephen B. Hanauer*, Henit Yanai, Emma Calabrese

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past two decades there has been an expanding database regarding the role of aminosalicylates for the treatment of Crohn's disease (CD). While initial evidence demonstrated a small, but clinically significant benefit for sulfasalazine in mild-moderate CD and the initial experience with mesalamine formulations was positive; evolving data from large, follow-up Phase III and investigator-initiated trials in active disease and in postoperative disease have been less supportive of an overall role. Nevertheless, there continues to be clinical support for treatment of mild, inflammatory CD with aminosalicylates and for maintaining 5-ASA induced remissions in responding patients.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Inflammatory Bowel Disease
Subtitle of host publicationNew Challenges: Second Edition
PublisherWiley Blackwell
Pages73-76
Number of pages4
ISBN (Print)9781444334548
DOIs
StatePublished - Jan 30 2012

Keywords

  • Aminosalicylates
  • Crohn's disease
  • Medical therapy
  • Mesalamine
  • Mesalazine
  • Sulfasalazine

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Why do we Still Use 5-ASAs in Crohn's Disease?'. Together they form a unique fingerprint.

Cite this